Cannabinoid Receptor

Signaling Pathway Map

Research Area

  • Inhibitory Selectivity
  • Solubility
Catalog No. Product Name Solubility(25°C)
Water DMSO Alcohol
S5119 Olivetol 100 mg/mL
S3021 Rimonabant <1 mg/mL 25 mg/mL 2 mg/mL
S2819 AM251 <1 mg/mL 40 mg/mL <1 mg/mL
S8012 Otenabant (CP-945598) HCl <1 mg/mL 5 mg/mL <1 mg/mL
S8694 CID16020046 (CID 16020046) <1 mg/mL 85 mg/mL <1 mg/mL
S1544 AM1241 <1 mg/mL 101 mg/mL <1 mg/mL
S2854 BML-190 <1 mg/mL 22 mg/mL <1 mg/mL
S2778 GW842166X <1 mg/mL 20 mg/mL <1 mg/mL
S1534 Org 27569 <1 mg/mL 82 mg/mL <1 mg/mL

Isoform-specific Inhibitors

Catalog No. Information Product Use Citations Product Validations
S5119New

Olivetol

Olivetol is a naturally occurring organic compound being a precursor in various syntheses of tetrahydrocannabinol. It acts as a competitive inhibitor of the cannabinoid receptors CB1 and CB2.

S3021

Rimonabant

Rimonabant is a selective antagonist of CB1 with IC50 of 13.6 nM and EC50 of 17.3 nM in hCB1 transfected HEK 293 membrane.

S2819

AM251

AM251 block the inhibitory effects of endocannabinoids and synthetic cannabinoid agonists on transmitter release through an action at presynaptic cannabinoid 1 receptors in brain.

S8012

Otenabant (CP-945598) HCl

Otenabant (CP-945598) HCl is a potent and selective cannabinoid receptor CB1 antagonist with Ki of 0.7 nM, exhibits 10,000-fold greater selectivity against human CB2 receptor. Phase 1.

S8694New

CID16020046 (CID 16020046)

CID16020046 is a selective GPR55 antagonist, inhibiting GPR55 constitutive activity with IC50 of 0.15 μM in yeast. It demonstrates weak activity against a broad spectrum of other GPCRs, ion channels, kinases, and nuclear receptor.

S1544

AM1241

AM-1241 is a selective cannabinoid CB2 receptor agonist with Ki of 3.4 nM, exhibits 82-fold selectivity over CB1 receptor.

S2854

BML-190

BML-190 is a selective cannabinoid CB2 receptor inverse agonist with Ki of 435 nM, with 50-fold selectivity over CB1 receptor.

S2778

GW842166X

GW842166X is a potent and highly selective agonist of cannabinoid receptor CB2 receptor with EC50 of 63 nM, shows no significant activity at CB1 receptor. Phase 2.

S1534

Org 27569

Org 27569 is an allosteric modulator of cannabinoid CB1 receptor, induces a CB1 receptor state that is characterized by enhanced agonist affinity and decreased inverse agonist affinity.

Tags: Cannabinoid Receptor signaling | CB1 receptor signaling | CB2 signaling | Cannabinoid Receptor inhibitor review